BSIM Therapeutics is awarded a second US Patent

For the second time around, BSIM Therapeutics has been awarded a United States Patent (Patent no. 11,117,877) for yet another novel technology directed to the treatment of transthyretin amyloidosis (ATTR). The protected chemical series of transthyretin (TTR) stabilizers represents a landmark advance in the pursuit of molecular “chaperones” displaying resilience towards mutations that affect TTR stability and binding affinity, while also encompassing a wide range of versatile, drug-like and safe compounds aimed at the organ-targeted treatment of ATTR.

With this new addition, BSIM takes a step forward in the consolidation of a strong Intellectual Property portfolio and in its efforts to answer to multiple unmet medical needs of ATTR patients.

More news soon. Stay tuned!